

ABN 13 009 607 676

246 Esplanade Brighton. Vic. 3186 Australia

Phone 613 9553 8896 Fax 613 9592 2328 admin@plentex.com.au www.plentex.com.au

16 November 2015.

#### **ASX ANNOUNCEMENT**

#### **ISSUE OF SHARES**

Plentex Limited (ASX: PRM) ("the Company") advises that it completed the issue of a total of 5,080,000 fully paid ordinary shares at an issue price of 10 cents per share, issued during the period 16 March 2015 to 21 May 2015.

The funds raised by this issue were utilised towards working capital.

Attached is the Company's Appendix 3B announcement relating to the issue of the ordinary shares.

For and on behalf of PLENTEX LIMITED

PETER C. STREADER Executive Chairman

#### **About Plentex**

Plentex Limited (ASX:PRM) is an algae based biotech company focused on the discovery, development and commercialisation of natural, efficacious, algae derived products for the pharmaceutical market.

Through harnessing strategic relationships with Australian and offshore research centres of excellence, Plentex is focusing its product range, product pipeline and research and development capabilities in the dermatology and VMS (vitamins, minerals and supplement) markets.

#### For further information contact:

Peter Streader Executive Chairman Plentex Limited

Telephone: +613 9553 8896 Email: pstreader@plentex.com.au Daniel Goldman Managing Director Plentex Limited

Telephone: +613 9553 8896 Email: dgoldman@plentex.com.au

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13		
Namo	e of entity	
PI	LENTEX LIMITED	
ABN		
13 (	009 607 676	
We	(the entity) give ASX the followin	g information.
	t 1 - All issues nust complete the relevant sections (attac	th sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Ordinary Shares (PRM)
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	5,080,000 ordinary shares
3	Principal terms of the  +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if  +convertible securities, the conversion price and dates for conversion)	Same as existing ordinary shares.

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	10 cents
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Proceeds of the placements used towards working capital.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	5,080,000
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
_	161 1 1 1	27/4	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining	N/A	
OI .	issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	<sup>+</sup> Issue dates		
7		16 March 2015	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in	19 March 2015	
	rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with	11 May 2015	
	the applicable timetable in Appendix 7A.	14 May 2015	
	Cross reference: item 33 of Appendix 3B.	21 May 2015	
		<b>F</b>	
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	49,560,106	Ordinary shares (PRM)

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	<sup>+</sup> Class
	7,460,000 Unlisted options exercisable before 30 September 2014 @ 25 cents (PRMAW) expired on that date.
	6,750,000 Unlisted "Executive" options exercisable before 30 November 2014 @ 30 cents (PRMAI) <u>expired</u> on that date.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Unchanged

## Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A

## Appendix 3B New issue announcement

18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A
	3 - Quotation of securities and only complete this section if you are a	
34	Type of *securities (tick one)	
(a)	*Securities described in Par	tı
(b)		nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es that have ticked box 34(a)	
Addit	ional securities forming a ne	w class of securities
Tick to docume	indicate you are providing the informatients	ion or
35		y securities, the names of the 20 largest holders of the the number and percentage of additional <sup>+</sup> securities
36	1 1	y securities, a distribution schedule of the additional number of holders in the categories
37	A copy of any trust deed for	the additional *securities

Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX	Number	<sup>+</sup> Class
	(including the *securities in clause 38)		

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Director/Company secretary)	Date: 16 November 2015
Print name:	PETER C. STREADER	
	== == == ==	

o4/o3/2013 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B - Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	
Add the following:	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	
"A"	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15		
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:		
Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"		
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15		
Note: number must be same as shown in Step 2		
Subtract "C"		
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"		
	[Note: this is the remaining placement capacity under rule 7.1]	

04/03/2013 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

# Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
0.10		
Note: this value cannot be changed		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

04/03/2013 Appendix 3B Page 13

<sup>+</sup> See chapter 19 for defined terms.